Literature DB >> 27135834

The Epidemiology of DSM-5 Nicotine Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions-III.

S Patricia Chou1,2, Risë B Goldstein2, Sharon M Smith2, Boji Huang2, W June Ruan2, Haitao Zhang2, Jeesun Jung2, Tulshi D Saha2, Roger P Pickering2, Bridget F Grant2.   

Abstract

OBJECTIVE: To present nationally representative information on the prevalence, correlates, psychiatric comorbidity, and treatment of DSM-5 nicotine use disorder (NUD) and the public health burden of US cigarette consumption among adults with NUD and other psychiatric disorders.
METHODS: Using data from the 2012-2013 National Epidemiologic Survey on Alcohol and Related Conditions-III (N = 36,309), we conducted weighted cross-tabulations and multivariate logistic regression analyses to estimate prevalences and examine comorbidity of NUD.
RESULTS: Prevalences of 12-month and lifetime DSM-5 NUD were 20.0% and 27.9%, respectively. Nicotine use disorder was more frequent among men, non-Hispanic whites, younger individuals, the previously married, those with less education and lower incomes, and those residing in rural areas. Adjusting for sociodemographic characteristics and additional psychiatric comorbidity, 12-month NUD and lifetime NUD were significantly associated with other substance use and antisocial personality disorders (odds ratios [ORs] = 1.5-5.1, 12-month; 1.5-5.6, lifetime). Twelve-month severe NUD was generally associated with major depressive, bipolar I, bipolar II, panic, generalized anxiety, posttraumatic stress, and schizotypal, borderline, and antisocial personality disorders (ORs = 1.3-2.5). Individuals with current NUD and at least 1 psychiatric disorder comprised 11.1% of US adults but smoked 53.6% of total cigarettes consumed. Treatment was utilized by 20.3% of respondents with 12-month and 18.8% with lifetime NUD.
CONCLUSIONS: Findings underscore the need to address nicotine use in clinical settings. Recognition of psychiatrically vulnerable subpopulations may inform etiologic research, prevention, and treatment of NUD. © Copyright 2016 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Year:  2016        PMID: 27135834      PMCID: PMC8154113          DOI: 10.4088/JCP.15m10114

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  41 in total

Review 1.  Sensitive questions in surveys.

Authors:  Roger Tourangeau; Ting Yan
Journal:  Psychol Bull       Date:  2007-09       Impact factor: 17.737

Review 2.  Are there genetic influences on addiction: evidence from family, adoption and twin studies.

Authors:  Arpana Agrawal; Michael T Lynskey
Journal:  Addiction       Date:  2008-05-20       Impact factor: 6.526

3.  Epidemiology of DSM-5 Alcohol Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions III.

Authors:  Bridget F Grant; Risë B Goldstein; Tulshi D Saha; S Patricia Chou; Jeesun Jung; Haitao Zhang; Roger P Pickering; W June Ruan; Sharon M Smith; Boji Huang; Deborah S Hasin
Journal:  JAMA Psychiatry       Date:  2015-08       Impact factor: 21.596

4.  Unemployment and substance outcomes in the United States 2002-2010.

Authors:  Wilson M Compton; Joe Gfroerer; Kevin P Conway; Matthew S Finger
Journal:  Drug Alcohol Depend       Date:  2014-06-19       Impact factor: 4.492

5.  Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions.

Authors:  Wilson M Compton; Yonette F Thomas; Frederick S Stinson; Bridget F Grant
Journal:  Arch Gen Psychiatry       Date:  2007-05

6.  Specifying cigarette smoking and quitting among people with serious mental illness.

Authors:  Alicia Lucksted; Colleen McGuire; Leticia Postrado; Julie Kreyenbuhl; Lisa B Dixon
Journal:  Am J Addict       Date:  2004 Mar-Apr

7.  Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions.

Authors:  Deborah S Hasin; Frederick S Stinson; Elizabeth Ogburn; Bridget F Grant
Journal:  Arch Gen Psychiatry       Date:  2007-07

8.  Smoking-attributable mortality, years of potential life lost, and productivity losses--United States, 2000-2004.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2008-11-14       Impact factor: 17.586

Review 9.  Epidemiology of diabetes.

Authors:  Nita Gandhi Forouhi; Nicholas J Wareham
Journal:  Medicine (Abingdon)       Date:  2014-12

10.  Current cigarette smoking among adults--United States, 2005-2013.

Authors:  Ahmed Jamal; Israel T Agaku; Erin O'Connor; Brian A King; John B Kenemer; Linda Neff
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2014-11-28       Impact factor: 17.586

View more
  40 in total

1.  Sexual Orientation, Adverse Childhood Experiences, and Comorbid DSM-5 Substance Use and Mental Health Disorders.

Authors:  Sean Esteban McCabe; Tonda L Hughes; Brady T West; Rebecca J Evans-Polce; Phil T Veliz; Kara Dickinson; Vita V McCabe; Carol J Boyd
Journal:  J Clin Psychiatry       Date:  2020-12-01       Impact factor: 4.384

2.  Principal component analysis of early alcohol, drug and tobacco use with major depressive disorder in US adults.

Authors:  Kesheng Wang; Ying Liu; Youssoufou Ouedraogo; Nianyang Wang; Xin Xie; Chun Xu; Xingguang Luo
Journal:  J Psychiatr Res       Date:  2018-02-24       Impact factor: 4.791

3.  Who are the smokers who never plan to quit and what do they think about the risks of using tobacco products?

Authors:  Lucy Popova; Ban Majeed; Daniel Owusu; Claire Adams Spears; David L Ashley
Journal:  Addict Behav       Date:  2018-06-27       Impact factor: 3.913

4.  Motives and perceptions regarding electronic nicotine delivery systems (ENDS) use among adults with mental health conditions.

Authors:  Claire Adams Spears; Dina M Jones; Scott R Weaver; Terry F Pechacek; Michael P Eriksen
Journal:  Addict Behav       Date:  2018-01-16       Impact factor: 3.913

5.  Polygenic liability for schizophrenia predicts shifting-specific executive function deficits and tobacco use in a moderate drinking community sample.

Authors:  Alex P Miller; Ian R Gizer; William A Fleming Iii; Jacqueline M Otto; Joseph D Deak; Jorge S Martins; Bruce D Bartholow
Journal:  Psychiatry Res       Date:  2019-06-18       Impact factor: 3.222

6.  Higher smoking prevalence among United States adults with co-occurring affective and drug use diagnoses.

Authors:  Maria A Parker; Stacey C Sigmon; Andrea C Villanti
Journal:  Addict Behav       Date:  2019-08-26       Impact factor: 3.913

7.  Psychiatric Disorders and Crime in the US Population: Results From the National Epidemiologic Survey on Alcohol and Related Conditions Wave III.

Authors:  Kelly E Moore; Lindsay M S Oberleitner; Howard V Zonana; Alec W Buchanan; Brian P Pittman; Terril L Verplaetse; Gustavo A Angarita; Walter Roberts; Sherry A McKee
Journal:  J Clin Psychiatry       Date:  2019-02-12       Impact factor: 4.384

8.  Relationship of negative urgency to cingulo-insular and cortico-striatal resting state functional connectivity in tobacco use.

Authors:  Miji Um; Tom A Hummer; Melissa A Cyders
Journal:  Brain Imaging Behav       Date:  2020-10       Impact factor: 3.978

9.  Association of DSM-5 Betel-Quid Use Disorder With Oral Potentially Malignant Disorder in 6 Betel-Quid Endemic Asian Populations.

Authors:  Chien-Hung Lee; Albert Min-Shan Ko; Frances M Yang; Chung-Chieh Hung; Saman Warnakulasuriya; Salah Osman Ibrahim; Rosnah Binti Zain; Ying-Chin Ko
Journal:  JAMA Psychiatry       Date:  2018-03-01       Impact factor: 21.596

10.  Epidemiology of DSM-5 Drug Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions-III.

Authors:  Bridget F Grant; Tulshi D Saha; W June Ruan; Risë B Goldstein; S Patricia Chou; Jeesun Jung; Haitao Zhang; Sharon M Smith; Roger P Pickering; Boji Huang; Deborah S Hasin
Journal:  JAMA Psychiatry       Date:  2016-01       Impact factor: 21.596

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.